# TREM2 supports neuronal protection and microglial reactivity without an effect on misfolded protein deposition in chronic neurodegenerative prion disease

**Authors:** Sarah M. Carpanini, Barry M. Bradford, Alessio Alfieri, Pedro Piccardo, Jimena Monzón-Sandoval, Deborah Brown, Aileen Boyle, Aleksandra Pokrovskaya, Neil A. Mabbott, Jean Manson, Barry W. McColl

PMC · DOI: 10.3389/fnins.2025.1525017 · 2025-05-07

## TL;DR

This study shows that TREM2 helps protect neurons and activate microglia during prion disease, but does not affect the buildup of misfolded proteins.

## Contribution

The study reveals TREM2's role in neuronal resilience and microglial reactivity in prion disease, independent of proteinopathy.

## Key findings

- TREM2 deficiency increases neuropathology severity in prion-infected mice.
- Microglial reactivity is reduced in TREM2-deficient mice during prion infection.
- TREM2 supports myelination gene expression in prion-infected mice.

## Abstract

Triggering receptor expressed on myeloid cells-2 (TREM2) variants have been identified as risk factors for neurodegenerative disease, including Alzheimer’s disease. TREM2 is a cell surface receptor on microglia that regulates homeostatic and immunomodulatory functions, including phagocytosis of apoptotic debris and the resolution of damage-associated inflammation. It remains unclear how TREM2 may mediate an influence on neurodegenerative disease, particularly in relation to key neuropathological hallmarks such as neuronal loss and proteinopathy.

We used the ME7 prion disease model to assess the role of TREM2 in the progression and pathology of neurodegenerative disease. Prion diseases are characterised by the accumulation of misfolded prion proteins and provide a highly tractable platform to determine if TREM2 has disease-modifying effects.

Trem2−/− and wild-type (WT) mice were inoculated intracerebrally with mouse-passaged ME7 scrapie prions, and their effects on CNS disease pathogenesis were determined. Although the accumulation of prion disease-specific PrP was similar in the brains of mice from each group, the severity of neuropathology was increased in Trem2−/− mice. Morphometric analysis of the microglia also indicated blunted disease-induced reactivity in the brains of infected Trem2−/− mice compared to wild-type (WT) controls. Expression of genes involved in myelination was reduced in prion-infected Trem2−/− mice compared to infected WT mice.

We conclude that during brain infection with prions, TREM2 supports microglial reactive changes associated with resilience to neuronal loss independently of affecting misfolded PrP deposition. These data imply that TREM2 status may be an important influence on the downstream response to CNS proteinopathy, which alters the susceptibility of neurons and brain tissue to proteinopathy-induced degenerative changes.

## Linked entities

- **Genes:** TREM2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 54209]
- **Proteins:** TREM2 (triggering receptor expressed on myeloid cells 2), C4BPA (complement component 4 binding protein alpha)
- **Diseases:** prion disease (MONDO:0005429), Alzheimer’s disease (MONDO:0004975)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Prnp (prion protein) [NCBI Gene 19122] {aka CD230, PrP, PrP<C>, PrPC, PrPSc, Prn-i}, Trem2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 83433] {aka TREM-2, Trem2a, Trem2b, Trem2c}
- **Diseases:** CNS disease (MESH:D002493), proteinopathy (MESH:D057165), neuronal loss (MESH:D009410), brain infection (MESH:D007239), neurodegenerative disease (MESH:D019636), Alzheimer's disease (MESH:D000544), inflammation (MESH:D007249), Prion diseases (MESH:D017096)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** ME7 — Homo sapiens (Human), Melanoma, Cancer cell line (CVCL_L914)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12093410/full.md

---
Source: https://tomesphere.com/paper/PMC12093410